Business Insider spoke to Eli Lilly's new president of cardiometabolic health, who shared the company's aggressive incretin ...

While Eli Lilly has struggled in the past year due to competitive pressures, the statistical winds may finally favor LLY ...

Eli Lilly's stock boomed April 17 after announcing a new experimental pill that caused nearly 8% weight loss at certain dosages and lowered blood sugar in patients during a clinical trial.. The ...

Ladies and gentlemen, let’s talk about Eli Lilly. There’s something curious about the chart below. Nvidia, the poster child of the AI revolution, has seen its share price skyrocket.

Eli Lilly saw its shares jump by 15% on Thursday after unveiling positive results from a clinical trial of its experimental oral drug. REUTERS Lilly’s stock was recently up 14% at $838.80 in ...

Eli Lilly said it has started selling single-dose vials of its uber-popular weight loss drug Zepbound as demand soars – and the smaller doses cost 50% less than all other obesity medicines.

On Tuesday, Eli Lilly announced that it would start selling low doses of its weight-loss drug Zepbound in vials, too — at a far lower price than its pens, which come with pre-filled doses.

Eli Lilly is offering vials of its weight-loss drug Zepbound to patients at a discount — but only if they skip their insurance. Novo Nordisk is now discounting Wegovy for cash customers too.

Eli Lilly (LLY-0.40%) stock is up a mammoth 770% in five years. It is trading at new all-time highs in 2024 thanks to the incredible success and popularity of its diabetes and weight loss products ...

Eli Lilly said that a four-week supply will cost $399 for 2.5 mg vials and $549 for 5 mg vials. The injector pen treatment plans of the popular weight-loss drugs from Lilly and Novo Nordisk can ...

Eli Lilly is set to announce Q3 earnings, with expectations of of $1.45 EPS and $12.10 billion in revenue. The stock’s remarkable rise positions Eli Lilly for a potential split, attracting more ...

Eli Lilly’s GLP-1 medications including Zepbound beat analysts’ estimates. Photo: Shelby Knowles/Bloomberg News. Novo Nordisk had a big head start in the race to dominate the weight-loss market.